摘要：目的：小儿黄龙止咳颗粒联合西药治疗儿童支气管哮喘临床效果的远期观察。方法：选取在我院2020.1-2021.8期间治疗的52例儿童支气管哮喘患者为研究对象，本次开展实验为对比探究实验，将52例儿童支气管哮喘患者随机分为实验组和对照组，每组26例患者，两组患者在临床治疗的过程中，均应用西药治疗，实验组患者在常规西药治疗的基础上，联合小儿黄龙止咳颗粒治疗，比较两组患者临床效果的远期观察效果。结果：治疗前，实验组患者中医症候积分为（5.86±1.23）分，对照组患者中医症候积分为（5.91±1.20）分，治疗前两组患者中医症候积分没有显著差异，采取不同治疗方案之后，实验组患者中医症候积分为（3.01±0.95）分，对照组患者中医症候积分为（4.86±1.03）分，实验组患者中医症候积分低于对照组患者，P<0.05;两组患者在治疗之前，两组患者的嗜酸性粒细胞（EOS）百分比和细胞免疫因子水平没有显著差异，在药物治疗之后，实验组患者嗜酸性粒细胞（EOS）百分比和细胞免疫因子水平优于对照组患者，P<0.05;实验组患者疾病复发率15.38%低于对照组患者46.15%疾病复发率，P<0.05;实验组患者平均疾病复发次数（1.56±0.65）次低于对照组患者（2.75±0.72）次平均疾病复发次数，P<0.05。结论：儿童支气管哮喘患者在臨床疾病治疗中，采取小儿黄龙止咳颗粒联合西药治疗方案，能够更好地帮助患者改善支气管哮喘疾病症状，降低患者炎性反应和改善患者免疫功能，患者在治疗之后复发率比较低，平均疾病复发次数也得到了优化，在儿童支气管哮喘患者临床治疗中，推广采取小儿黄龙止咳颗粒联合西药治疗方案。

关键词：儿童支气管哮喘;小儿黄龙止咳颗粒;西药治疗;临床效果

[Abstract] Objective： Long-term observation of the clinical effect of pediatric Huanglong cough granules combined with western medicine for pediatric bronchial asthma.Methods： selected in our 2020.1-2021.8 treatment of 52 pediatric bronchial asthma patients as the research object，the experiment for comparative experiment，52 cases of pediatric bronchial asthma patients randomly divided into experimental group and control，each group，26 patients，two groups of patients in the process of clinical treatment，on the basis of conventional western medicine treatment，combined pediatric Huanglong cough granule treatment，compare the clinical effect of clinical effect.Results： Before the treatment，The TCM syndrome score in the experimental group was （5.86 ± 1.23），TCM syndrome score was （5.91 ± 1.20），There was no significant difference in TCM syndrome points between the two groups before treatment，After taking the different treatment options，The TCM syndrome score in the experimental group was （3.01 ± 0.95），The TCM syndrome score was （4.86 ± 1.03），Patients in the experimental group had lower TCM syndrome scores than those in the control group，P<0.05; Two groups of patients were prior to treatment，There were no significant difference in the percentage of eosinophils （EOS） and cytoimmunkine levels in the two groups，After the drug treatment，Experimental patients had superior eosinophil （EOS） percentage and cytoimmunkine levels compared to control patients，P<0.05; The disease recurrence rate of the experimental group was 15.38% lower than 46.15% in the control group，P<0.05; The mean number of disease relapses （1.56 ± 0.65 in the experimental group） was lower than the mean number of disease relapses in control patients （2.75 ± 0.72），P<0.05. Conclusion： pediatric bronchial asthma patients in clinical disease treatment，take pediatric Huanglong cough particles combined with western medicine treatment scheme，can better help patients improve bronchial asthma symptoms，reduce inflammatory reaction and improve the immune function，patients after treatment recurrence rate is low，the average number of disease recurrence has been optimized，in the clinical treatment of pediatric bronchial asthma patients，promote the adoption of pediatric Huanglong cough particles combined with western medicine treatment scheme.